Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

BioNTech Stock Pops on Big Sales Beat

Published 05/09/2022, 09:18 PM
Updated 05/09/2022, 09:18 PM
© Reuters.

Shares of BioNTech (NASDAQ:BNTX) are up around 1.5% in pre-open Monday after the biotech company reported better-than-expected Q1 EPS and revenue.

The German biotechnology company reported a Q1 EPS of €14.24, up from €4.39 in the year-ago period and the consensus estimates of €8.62. Revenue came in at €6.37, topping the estimated €4.01 billion.

In the first quarter, BioNTech generated €1.16 billion in direct coronavirus vaccine sales in Germany and Turkey, in addition to €603.2 million in sales of products made by BioNTech for its partners.

Commercial revenues in the first quarter included €4.59 billion gross profit share in territories allocated between Pfizer (NYSE:PFE), BioNTech, and Fosun Pharma (SS:600196) (HK:2196).

For the full fiscal year, BNTX expects capital expenditure in the range of €450 million to €550 million, while analysts were looking for €390.3 million. Coronavirus vaccine revenue is expected to be in the range of €13 billion to €17 billion, compared to the consensus projection of €15.62 billion.

By Senad Karaahmetovic

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.